Related Experiment Video
Updated: Feb 15, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab
Benoit Meunier1, Audrey Rico2, Julie Seguier1
1Département de médecine interne, Hôpital de la Timone, APHM, Marseille France.
Background:
Alemtuzumab is a humanized monoclonal antibody directed at CD52 approved as a disease-modifying therapy for relapsing forms of multiple sclerosis (MS).
Objective:
To describe a case of a life-threatening autoimmune anemia occurring after a first course of alemtuzumab for relapsing-remitting MS in a 28-year-old male.
Methods:
Case report.
Results:
A 28-year-old male developed a life-threatening autoimmune anemia occurring 11 months after first alemtuzumab course.
Conclusion:
We report the third case of autoimmune hemolytic anemia following treatment with alemtuzumab in a young MS patient. Due to the severity of this adverse event, neurologists using this treatment should be alert.
Related Concept Videos
Half-life of a Reaction
The Angiosperm Life Cycle
Characteristics of Life
The Tree of Life - Bacteria, Archaea, Eukaryotes
Multiple Allele Traits
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...

